REGRANEX
Commercial- Indications
- Diabetic foot ulcers
Company intelligence / Profile preview
Lynch Regenerative Medicine (LRM) develops and commercializes advanced regenerative skincare products based on proprietary recombinant human Platelet-Derived Growth Factor. Their lead product Ariessence™ Pure PDGF+ is commercially available for skin rejuvenation in med/spa clinics and aesthetic practices. The company also acquired REGRANEX® Gel—the only FDA-approved PDGF therapy for diabetic neuropathic ulcers—expanding their reach into advanced wound care. The technology has a strong clinical foundation with over five million patients treated using related products over the past fifteen years.[2][4][7]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LRM Aesthetics.